To hear about similar clinical trials, please enter your email below

Trial Title: Integrative Omics Analysis for Colorectal Cancer and Metastasis

NCT ID: NCT05482529

Condition: Colorectal Cancer

Conditions: Official terms:
Colorectal Neoplasms
Neoplasm Metastasis

Conditions: Keywords:
Integrative omics
colorectal cancer
distant metastasis
prognostic analysis

Study type: Observational [Patient Registry]

Overall status: Recruiting

Study design:

Time perspective: Prospective

Intervention:

Intervention type: Other
Intervention name: Integrative omics
Description: Integrative omics such as RNA-sequencing,ATAC-seq(Assay for Transposase-Accessible Chromatin using sequencing), CUT&Tag( Cleavage Under Targets and Tagmentation)to analyze and predict candidate biomarkers of colorectal cancer and distant metastasis.
Arm group label: colorectal cancer with metastasis

Summary: The pathogenesis of Colorectal cancer (CRC) metastasis remains unclear.We collect clinical data from our center and use Integrative omics to analyze and predict candidate biomarkers of colorectal cancer and distant metastasis.

Detailed description: Colorectal cancer (CRC), one of the most common malignant cancer around the world, CRC patients with distant metastasis. However, the pathogenesis of metastasis remains unclear. Integrative omics have begun to enable personalized medicine at an extraordinarily detailed molecular level. All patients with colorectal cancer and metastasis in our center who meet the inclusion criteria and exclusion criteria will be enrolled. The specimen collected by surgery and clinical data will be collected . We use Integrative omics such as RNA-sequencing,ATAC-seq(Assay for Transposase-Accessible Chromatin using sequencing), CUT&Tag( Cleavage Under Targets and Tagmentation)to analyze and predict candidate biomarkers of colorectal cancer and distant metastasis. This study will contribute to understanding the molecular mechanism of CRC metastasis in depth and contribute to the discovery of new appropriate molecular diagnostic and therapeutic targets, and more accurately prognose long term outcome in patients with CRC.

Criteria for eligibility:

Study pop:
All patients with colorectal cancer and metastasis will be enrolled.

Sampling method: Non-Probability Sample
Criteria:
Inclusion Criteria: - colorectal adenocarcinoma by biopsy。 - at least 1 metastasis lesion comfirmed by at least 1 kind of imaging examination (CT, MRI and PET-CT ) Exclusion Criteria: - recent diagnosis with other malignancies - can not tolerate the surgery - history of serious mental illness - pregnancy or lactating women - the researchers believe the patients should not enrolled in

Gender: All

Minimum age: 18 Years

Maximum age: N/A

Locations:

Facility:
Name: Daping hospital

Address:
City: Chongqing
Zip: 400042
Country: China

Status: Recruiting

Contact:
Last name: fan Li, PhD

Phone: 68729350
Email: levinecq@163.com

Start date: August 1, 2022

Completion date: December 31, 2025

Lead sponsor:
Agency: fan li
Agency class: Other

Source: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05482529

Login to your account

Did you forget your password?